Multiplicom is pleased to announce the release of the TP53 MASTR molecular assay, research use only, for the identification of mutations in the entire coding region of TP53.

TP53 is the most frequently mutated gene in cancer and is associated with Li-Fraumeni syndrome, an inherited cancer syndrome. The TP53 MASTR is designed for intended use both on germline material as well as FFPE material.
NGS-based analysis of TP53 mutations has a wide variety of clinical and research applications.

Germline mutation detection

• for cancer predisposition testing (e.g. Li-Fraumeni syndrome)

Somatic mutation detection

• for molecular tumor classification and as prognostic biomarker (including leukemia (e.g. CLL, Non-Hodgekin lymphoma), sarcomas, bladder and esophageal cancer)
• for prediction of therapeutic success (e.g. TP53-targeting drugs and MDM2 inhibitors)
• for clonality analysis to discriminate primary tumors and metastases

The TP53 MASTR has several advantages:

• clear clinical guidelines to use the test
• compatible with DNA derived from both FFPE tumor samples and blood